Results 121 to 130 of about 28,869 (265)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate

Scientific Reports
This study aimed to compare the serum lipid profiles between tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in the long-term treatment of chronic hepatitis B (CHB). We analyzed data from treatment-naïve CHB patients administered with
Shenglong Lin, Wan Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao   +7 more
semanticscholar   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy

Drug Design, Development and Therapy, 2017
Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj  

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

Journal of Antimicrobial Chemotherapy
Objective Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the efficacy of B/F/TAF was non-inferior to dolutegravir (DTG) + 2 NRTIs.
Kristen N. Andreatta, Paul E. Sax, D. Wohl, M. D’Antoni, Hui C. Liu, J. Hindman, Christian Callebaut   +6 more
semanticscholar   +1 more source

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials [PDF]

, 2020
Background: In the primary week-48 analyses of two phase 3 studies, coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir-containing regimen in treatment-naive people with HIV.
Acosta, R, Arribas, JR, Brainard, DM, Brinson, C, Clarke, A, Collins, SE, DeJesus, E, Flamm, JA, Gupta, SK, Hagins, D, Huang, H, Investigator, G-US, Investigator, G-US, Maggiolo, F, Martin, H, Martorell, C, Orkin, C, Podzamczer, D, Sax, PE, Stellbrink, H-J, Stephens, JL, Thompson, MA, Wohl, D   +22 more
core   +1 more source

Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B

Gut and Liver
Background/Aims Besifovir dipivoxil maleate (BSV) and tenofovir alafenamide fumarate (TAF) have been recently approved in Korea as the initial antiviral agents for chronic hepatitis B (CHB).
Tae Hyung Kim, Ji Hoon Kim, H. Yim, Y. S. Seo, S. Yim, Young-Sun Lee, Y. Jung, J. Yeon, S. Um, K. Byun   +9 more
semanticscholar   +1 more source

Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. [PDF]

, 2019
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia, due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or malignancies.
Bikle, Daniel, Kim, Sarah, Kim, Stephanie J, Peluso, Michael J, Shoback, Dolores, Wang, Yongmei   +5 more
core  

DETERMINANTS OF ANTI-RETROVIRAL THERAPY DRUG-RELATED TOXICITIES IN HIV POSITIVE PATIENTS [PDF]

Antiretroviral therapy (ART) drugs have increasingly been shown to contribute significantly to the morbidity of HIV positive patients exposed to them. This is more so with increasing survival of HIV patients since the introduction of ART.
Danjuma, MI, Danjuma, MI
core   +1 more source

Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

Вопросы вирусологии
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF).
Ekaterina N. Ozhmegova, Anna I. Kuznetsova, Aleksey V. Lebedev, Anastasia A. Antonova, Kristina V. Kim, Yana M. Munchak, Alexander S. Tumanov, Elena V. Kazennova   +7 more
doaj   +1 more source

Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B

Journal of Viral Hepatitis
Tenofovir alafenamide (TAF), a prodrug of tenofovir, delivers high levels of active drug to hepatocytes and is given in a lower dose than tenofovir disoproxil fumarate (TDF).
S. Hige, Kouji Aoki, Daisuke Nakamoto, John F Flaherty, Irina Botros, Hajime Mizutani, A. Ishizaki, Hiroki Konishi, Jason Yuan, M. Jinushi, Leslie J Ng   +10 more
semanticscholar   +1 more source